Blue Water Acquisition Corp. III Class A Ordinary Shares (BLUW)

FairStock Score: 19/100 — RISKY

Key Financials

Current Price$10.4
Market Cap$332M
P/E Ratio-47.27
ROE—%
Dividend Yield0%
SectorFinancial Services

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach this as a Graham-style balance-sheet question, and Blue Water Acquisition Corp. III is not an operating business. It is a 2024-incorporated shell with no significant operations, seeking a merger in AI, biotechnology, healthcare, or technology. In every filed period shown, revenue is n/a. The only earnings are net income: fiscal Q2 2026 ended 2026-06-30 was $2.1 million; fiscal Q1 2026 ended 2026-03-31 was $1.9 million; fiscal Q3 2025 ended 2025-09-30 was $2.3 million; fiscal Q2 2025 ended 2025-06-30 was $444,392; and FY2025 ended 2025-12-31 was $4.7 million. That does not create a durable moat, and without revenue I cannot assess pricing power, returns on capital, or organic growth. FairStock's calculations at the 2026-10-13 close of $10.39 show a P/E of -47.23, EPS of -$0.22, FCF of -$1.3 million, FCF yield of -0.4%, Piotroski F-Score 2/9, Altman Z-Score 20.68, and a FairStock Score of 19/100. The high Z-score suggests low near-term bankruptcy risk by that model, but the low F-score and negative free cash flow point to weak operating fundamentals. The provided profit growth of 372.14% is not meaningful to me without revenue and a multi-year record, and the computed Lynch category is none because only one year of filed results exists. At $10.39, near the 52-week high of $10.41, much of the value depends on finding and completing a merger, not on proven earning power. Graham would demand a margin of safety; here the asset is mostly deal optionality, not a bargain business. Buffett would stay in the too-hard pile.

In plain English: Blue Water Acquisition Corp. III is a blank-check company with no real operations; it plans to merge with a business in areas like artificial intelligence, biotechnology, healthcare, or technology. It has no revenue in the filed periods, reports a loss of $0.22 per share, and used $1.3 million more cash than it generated. At $10.39 on 2026-10-13, the price is near the top of its 52-week range, so it does not look cheap on the numbers; the value depends mostly on a future merger.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer